🔗 Share this article

As the United States undertakes historic revisions to its vaccination schedules, a particular individual has emerged unexpectedly: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccinations throughout the pandemic and has concentrated on potential deaths after Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Schedule

Agency leaders were set to reveal major changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s immunization schedule, it is understood – a major change that would put the US at odds with a large portion of the international standard with little proof for improved outcomes. This reveal has been delayed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is listed to speak at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to head the center this year.

A Shift at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad consolidate power at the agency – and it signals a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for halting certain childhood shot schedules in the US to become more like Denmark's approach, a society with nationalized medicine and a population about the size of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccines – usually the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Background

Dr. Høeg has no obvious track record in medication creation, approval processes or leadership, which has been typical for former directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since March.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in leading a large organization. She lacks background in industry regulation.”

Previous directors of the center would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that former directors who led CBER have had.”

This division has an immense range of responsibilities at the FDA, she pointed out.

“The public just focuses on the new drug program, but the generic drug division authorizes a multitude of generic drugs. There is also a biosimilars division, OTC medication office and so forth, and each of these have to be supervised,” she explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial administrative aspect to the job, which supervises in excess of 5,000 personnel. “It is a huge leadership role, if you do it right,” the former official said.

Agency Reaction and Disputed Programs

Regarding questions about Dr. Høeg's qualifications and whether this appointment indicates increased cooperation among regulatory chiefs on immunizations, a representative said that the “inquiries stem from incorrect premises”.

“Her resume matches the duties of her position,” the official said, pointing to the time Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a controversial expedited drug-approval program that allegedly worried her preceding directors. “How are these medications being picked for this fast-track system? Who takes the choices?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

In general, he stated, “the agency appears to be shifting towards less stringent rules of all drugs, with the exception of vaccines.”

Public Track Record on Vaccines

With immunizations, Dr. Høeg has a more established, if problematic, track record, some experts said. She authored a study using unconfirmed crowd-sourced reports to determine the frequency of heart inflammation following COVID-19 immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are riskier than they are.

Among her “desired changes” for the current federal leadership featured altering guidelines for new vaccines and ending “non-essential” immunizations, she said following the vote on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of preventing teenage boys from obtaining Covid vaccines.

“She is an complete ideologue who begins with her beliefs and tailors the evidence to fit the evidence in a very misleading, fraudulent manner,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with fellow dissenters, {like|